Methodological considerations for treatment trials for persons with borderline personality disorder

Annals of Clinical Psychiatry

Volumn 22, Issue 2, 2010, Pages 75-83

  Zanarini, Mary C ^a   Stanley, Barbara ^a   Black, Donald W ^a   Markowitz, John C ^a   Goodman, Marianne ^a   Pilkonis, Paul ^a   Lynch, Thomas R ^a   Levy, Kenneth ^a   Fonagy, Peter ^a   Bohus, Martin ^a   Farrell, Joan ^a   Sanislow, Charles ^a  

^a NONE

Author keywords

Borderline personality disorder; Guidelines; Treatment

Indexed keywords

BORDERLINE STATE; CLINICAL RESEARCH; HUMAN; INTERNATIONAL COOPERATION; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; STUDY DESIGN; CLASSIFICATION; CLINICAL TRIAL; PATIENT SELECTION;

PSYCHOTROPIC AGENT;

BORDERLINE PERSONALITY DISORDER; CLINICAL TRIALS AS TOPIC; HUMANS; PATIENT SELECTION; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RESEARCH DESIGN;

EID: 77956994498     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Akiskal HS, Chen SE, Davis GC, et al. An adjective in search of a noun. J Clin Psychiatry. 1985;46:41-48.
2. Lieb K, Zanarini MC, Schmahl C, et al. Borderline personality disorder. Lancet. 2004;364:453-461. (Pubitemid 39036894)
3. Cowdry R, Gardner DL. Pharmacotherapy of borderline personality disorder-alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119. (Pubitemid 18052841)
4. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29.
5. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238-246. (Pubitemid 19198957)
6. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377-385. (Pubitemid 23143127)
7. Bogenschutz MP, Nurnberg GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
8. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446. (Pubitemid 34507223)
9. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199-203. (Pubitemid 32270095)
10. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624. (Pubitemid 40343936)
11. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo study. J Clin Psychopharmacol. 2006;26:61-66. (Pubitemid 43167093)
12. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double blind placebo-controlled study. J Clin Psychiatry. 2004;65: 1515-1519.
13. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495-499. (Pubitemid 40311984)
14. Rinne T, van den Brink W, Wouters L, et al. SSRI treatment of borderline personality disorder: a randomized placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048-2054. (Pubitemid 35423864)
15. Schulz SC, Camlin KL, Berry S, et al. Risperidone for borderline personality disorder: A double-blind study. Presented at Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN, 1999.
16. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224. (Pubitemid 40770712)
17. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287-291. (Pubitemid 40694947)
18. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854. (Pubitemid 33131170)
19. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167-169. (Pubitemid 36042442)
20. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903-907.
21. Linehan MM, Armstrong HE, Suarez A, et al. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1991; 48:1060-1064.
22. Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry. 1999;156:1563-1569. (Pubitemid 29459988)
23. Blum N, St. John D, Pfohl B, et al. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1- year follow-up. Am J Psychiatry. 2008;165:468-478. (Pubitemid 351694290)
24. Bohus M, Haaf B, Stiglmayr C, et al. Evaluation of inpatient dialectical-behavioral therapy for borderline personality disorder - a prospective study. Behav Res Ther. 2000;38:875-887. (Pubitemid 30336422)
25. Clarkin JF, Levy KN, Lenzenweger MF, et al. Evaluating three treatments for borderline personality: a multiwave study. Am J Psychiatry. 2007;164:922-928. (Pubitemid 46972908)
26. Davidson K, Norrie J, Tyrer P, et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. J Pers Disord. 2006;20:450-465. (Pubitemid 44580879)
27. Farrell JM, Shaw IA, Webber MA. A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2009;40:317-328.
28. Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder. Arch Gen Psychiatry. 2006;63:649-658.
29. Koons CR, Robins CJ, Tweed JL, et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy. 2001;32:371-390. (Pubitemid 32995880)
30. Linehan MM, Schmidt H 3rd, Dimeff LA, et al. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict. 1999;8:279-292.
31. Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation plus 12- step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;67:13-26. (Pubitemid 34615925)
32. Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs. therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006;63:757-766.
33. Turner RM. Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. In: Turner RM, Marlatt GA, Albano AM, eds. Cognitive and behavioral practice, special series dialectical behavior therapy: Adaptations and new applications. New York, NY: Association for Advancement of Behavior Therapy; 2000:413-419 (Pubitemid 32115190)
34. Verheul R, Van Den Bosch LM, Koeter MW, et al. Dialectical behavior therapy for women with borderline personality disorder: 12-month randomized clinical trial in The Netherlands. Br J Psychiatry. 2003;182:135-140. (Pubitemid 36177236)
35. Zanarini MC, Frankenburg FR. A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. J Pers Disord. 2008;22:284-290.
36. Stangl D, Phofl B, Zimmerman M, et al. A structured interview for the DSM-III personality disorders. A preliminary report. Arch Gen Psychiatry. 1985;42:591-596. (Pubitemid 15058336)
37. Loranger AW, Susman VL, Oldham JM, et al. The Personality Disorder Examination: a preliminary report. J Pers Disord. 1987;1:1-13.
38. Zanarini MC, Frankenburg FR, Chauncey DL, et al. The diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Compr Psychiatry. 1987;28:467-480. (Pubitemid 18018773)
39. First MB, Spitzer RL, Gibbon M, Williams JBW. The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). Part II: multisite test-retest reliability study. J Pers Disord. 1995;9:92-104.
40. Zanarini MC, Gunderson JG, Frankenburg FR, et al. The revised diagnostic interview for borderlines: discriminating BPD from other Axis II disorders. J Pers Disord. 1989;3:10-18. (Pubitemid 19123799)
41. Zanarini MC, Frankenburg FR, Vujanovic AA. Inter-rater and test-retest reliability of the Revised Diagnostic Interview for Borderlines. J Pers Disord. 2002;16:270-276. (Pubitemid 34734446)
42. Zanarini MC, Silk KR. Dilemmas in the treatment of severe borderline personality disorder. In: Dewan MJ, Pies R. eds. The difficult-to-treat psychiatric patient. Arlington, VA: American Psychiatric Publishing, Inc.; 2001.
43. Gunderson JG. Borderline personality disorder. Washington DC: American Psychiatric Press; 1984.
44. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
45. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1978:217-222.
46. Zanarini MC, Vujanovic AA, Parachini E, et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): A continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003;17: 233-242. (Pubitemid 36741563)
47. Zanarini MC, Frankenburg FR. Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study. Compr Psychiatry. 2001;42:369-374. (Pubitemid 32884844)
48. Pfohl B, Blum N, McCormick B, et al. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a new scale to measure severity and change in borderline personality disorder. J Pers Disord. 2009;23:281-293.
49. Arntz A, van den Hoorn M, Cornelis J, et al. Reliability and validity of the borderline personality disorder severity index. J Pers Disord. 2003;17:45-59. (Pubitemid 36343239)
50. McGlashan TH, Grilo CM, Skodol AE, et al. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand. 2000;102:256-264.
51. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155:1733-1739. (Pubitemid 28547499)
52. Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry. 1991;40:245-252.
53. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634. (Pubitemid 36750138)
54. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry. 2001;158:295-302. (Pubitemid 32116528)
55. Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry. 2004;65:28-36.
56. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry. 2004;65:1660-1665.
57. Bohus M, Limberger MF, Frank U, et al. Psychometric properties of the Borderline Symptom List (BSL). Psychopathology. 2007;40:126-132. (Pubitemid 46220187)
58. Frank J. Therapeutic factors in psychotherapy. Am J Psychother. 1971;25:350-361.
59. Bootzin RR, Bailey ET. Understanding placebo, nocebo, and iatrogenic treatment effects. J Clin Psychol. 2005;61:871-880. (Pubitemid 41153536)
60. Gabbard GO. Do all roads lead to Rome? New findings on borderline personality disorder. Am J Psychiatry. 2007;164:853-855. (Pubitemid 46972897)
61. Baskin TW, Tierney SC, Minami T, et al. Establishing specificity in psychotherapy: a meta-analysis of structural equivalence of placebo controls. J Consult Clin Psychol. 2003;71:973-979. (Pubitemid 37448887)
62. Gratz KL, Gunderson JG. Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behav Ther. 2006;37: 25-35. (Pubitemid 44141942)
63. Weinberg I, Gunderson JG, Hennen J, et al. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. J Pers Disord. 2006;20:482-492. (Pubitemid 44580881)
64. Livesley WJ. A framework for integrating dimensional and categorical classifications of personality disorder. J Pers Disord. 2007;21:199-224. (Pubitemid 46743454)
65. Costa PT, McCrae RR. Professional Manual: Revised NEO Personality Inventory (NEO PI-R) and NEO Five Factor Inventory (NEO-FFI). Odessa, FL: Psychological Assessment Resources; 1992.
66. Clark LA. Manual for the Schedule for Nonadaptive and Adaptive Personality (SNAP). Minneapolis, MN: University of Minnesota Press; 1993.
67. Livesley WJ, Jackson DN. Manual for the Dimensional Assessment of Personality Problems - basic questionnaire (DAPP-BQ). Port Huron, MI: Sigma Assessment Systems; 2005-2007.